BPG is committed to discovery and dissemination of knowledge
Review
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Oct 27, 2025; 17(10): 111672
Published online Oct 27, 2025. doi: 10.4240/wjgs.v17.i10.111672
Intestinal reengineering: Scientific advances in intestinal transplantation
Yao Rong, Chen-Yang Nie, Ji-Dian Zhou, Zi-Cheng Wang, Di-Lin Wu, Sheng-Wei Wu, Zheng-Yong Xie
Yao Rong, Ji-Dian Zhou, Zi-Cheng Wang, Di-Lin Wu, Sheng-Wei Wu, Zheng-Yong Xie, Department of General Surgery, The General Hospital of Southern Theater Command, Guangzhou 510000, Guangdong Province, China
Chen-Yang Nie, Department of Quality Management, The General Hospital of Southern Theater Command, Guangzhou 510000, Guangdong Province, China
Co-first authors: Yao Rong and Chen-Yang Nie.
Co-corresponding authors: Sheng-Wei Wu and Zheng-Yong Xie.
Author contributions: Author contributions: Rong Y, Nie CY and Xie ZY conceived the study; Zhou JD collected the relevant data; Wang ZC and Wu DL created the figures and tables; Rong Y wrote a draft; Wu SW and Xie ZY reviewed and revised the manuscript; Rong Y and Nie CY contributed equally to this work; Xie ZY and Wu SW are co-corresponding authors; All authors read and approved the final manuscript. Both Wu SW and Xie ZY have played critical and indispensable roles as the co-corresponding authors. Wu SW was instrumental in the critical revision of the manuscript for important intellectual content, provided expert guidance on surgical and technical aspects of intestinal transplantation, and supervised the integration of clinical data. Xie ZY conceptualized and designed the research, secured funding, provided overall supervision of the project, and was responsible for the final approval of the manuscript version to be published. Their collaborative leadership was essential to the completion and refinement of this review.
Supported by Guangdong Provincial Medical Research Fund General Program, No. B2025209; and Guangzhou Science and Technology Program Project, No. 2025A03J3269.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zheng-Yong Xie, Chief Physician, Professor, Department of General Surgery, The General Hospital of Southern Theater Command, No. 111 Liuhua Road, Yuexiu District, Guangzhou 510000, Guangdong Province, China. pwkxiezy@163.com
Received: July 6, 2025
Revised: July 20, 2025
Accepted: September 2, 2025
Published online: October 27, 2025
Processing time: 110 Days and 18.9 Hours
Core Tip

Core Tip: This review systematically elucidates the current status and challenges of intestinal transplantation (ITx) as a life-saving therapy for patients with irreversible intestinal failure. Despite therapeutic hurdles such as the high immunogenicity of the intestine, complex microbiota microenvironment, and susceptibility to rejection, surgical innovations-including robot-assisted vascular anastomosis and multivisceral transplantation-along with breakthroughs in ex vivo perfusion technology have significantly improved clinical outcomes. This review highlights that bidirectional immune reactions (host-vs-graft response and graft-vs-host disease) and chronic rejection remain the primary clinical obstacles. Analysis herein reveals marked differences in immunological profiles and clinical manifestations between pediatric and adult recipients, necessitating individualized treatment strategies. Based on current research advances, future directions include precision immunotherapy, gut microbiota modulation, and bioengineering innovations such as 3D bioprinted grafts. The review emphasizes that only through multidisciplinary collaboration can ITx evolve into a safer and more effective treatment, ultimately achieving comprehensive improvements in long-term survival rates and quality of life for patients.